Protara Therapeutics, Inc. 8-K

What Happened
Protara Therapeutics, Inc. (TARA) held its Annual Meeting on June 12, 2026 (record date April 15, 2026, with 55,060,500 shares outstanding). Stockholders elected three Class III directors (Jesse Shefferman, Barry Flannelly, Pharm.D., and Cynthia Smith) and approved several proposals including ratification of Ernst & Young LLP as independent auditor, an advisory approval of named executive officer compensation (say-on-pay), a one-year frequency for future advisory votes on pay, an amendment to the 2024 Equity Incentive Plan, an increase in authorized common shares from 100,000,000 to 200,000,000, and officer exculpation under Delaware law.

Key Details

• Record date and shares outstanding: 55,060,500 as of April 15, 2026.
• Director elections (Class III): Jesse Shefferman — 26,672,259 for; Barry Flannelly — 25,409,066 for; Cynthia Smith — 22,371,125 for. (Broker non-votes: 14,185,811.)
• Auditor ratified: Ernst & Young LLP — 45,012,036 for, 74,615 against, 13,025 abstentions.
• Governance and plan votes: Say-on-pay advisory — 29,208,205 for; Say-on-pay frequency — majority for one year (26,766,824). Equity Incentive Plan amendment — 18,094,953 for, 12,793,033 against. Authorized shares increase — 42,417,621 for, 2,655,416 against. Officer exculpation — 29,642,641 for, 1,235,007 against.

Why It Matters
These outcomes finalize the board composition and ratify the auditor for 2026, both important for corporate oversight and financial reporting. Approval to double authorized common shares (100M to 200M) and the equity plan amendment give the company legal capacity to issue more shares or awards in the future. The advisory say-on-pay and one-year frequency reflect stockholder feedback on executive compensation. The officer exculpation amendment aligns the charter with Delaware law regarding officer liability. Investors should note the vote totals and sizable broker non-votes, which can affect vote outcomes on contested or shareholder-sensitive items.